Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects

PHASE4CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

December 31, 2010

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Inhaled treprostinil

Trial Locations (15)

10021

Cornell University Medical Center, New York

10032

Columbia Presbyterian Medical Center, New York

11040

Long Island Jewish Medical Center - North Shore, New Hyde Park

14623

Mary M. Parkes Center for Asthma, Allergy and Pulmonary Care, Rochester

15212

Allegheny General Hospital, Pittsburgh

15213

University of Pittsburg Medical Center, Pittsburgh

27710

Duke University Medical Center, Durham

35294

University of Alabama Birmingham, Birmingham

37232

Vanderbilt University Medical Center, Nashville

43210

Ohio State University Medical Center, Columbus

66160

Kansas University Medical Center, Kansas City

77030

Baylor College of Medicine, Houston

82037

UCSD Medical Center, La Jolla

90095

Ronald Reagan UCLA Medical Center, Los Angeles

10003-3314

Beth Israel Medical Center, New York

Sponsors
All Listed Sponsors
lead

United Therapeutics

INDUSTRY

NCT00741819 - Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects | Biotech Hunter | Biotech Hunter